Avai Bio Reports Increased Net Loss and Strategic Acquisitions in Latest Financial Results

Avai Bio, Inc. (formerly Avant Technologies Inc.) reported its financial results for the three months ending June 30, 2026, revealing a net loss of $552,041, an increase of 13% from the $487,589 loss recorded in the same period last year. The company did not generate any revenue during this quarter, consistent with the previous year. Total operating expenses decreased by 14% to $419,783, down from $487,589, primarily due to reduced marketing and professional fees. The increase in net loss was attributed to a rise in other expenses, which totaled $132,258, compared to none in the prior year.

As of June 30, 2026, Avai Bio's total assets amounted to $791,750, a significant increase from $572,696 as of March 31, 2026. This growth was driven by an increase in cash and cash equivalents, which rose to $83,586 from $23,145, and a rise in intangible assets, which increased to $158,898 from $105,542. However, the company also reported a working capital deficit of $3,860,035, up from $3,298,511 at the end of the previous fiscal period. Stockholders’ deficit increased to $3,222,566 from $2,815,155, reflecting ongoing financial challenges.

In terms of strategic developments, Avai Bio has been active in acquiring technology assets. The company completed the acquisition of Avant! AI and Instant Fame technologies in April 2023, which are expected to enhance its capabilities in artificial intelligence and digital asset management. Additionally, the company entered into joint ventures with Ainnova Tech Inc. and SGAustria Pte. Ltd. to develop healthcare and biotechnology solutions, respectively. These initiatives are part of Avai Bio's strategy to expand its technological portfolio and market presence.

Operationally, the company has not reported any significant customer growth or engagement metrics, as it continues to focus on product development rather than revenue generation. The employee headcount remains unspecified, but the company has indicated a need for additional personnel to support its growth objectives. Avai Bio's management has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for additional capital to fund operations and achieve profitability.

Looking ahead, Avai Bio anticipates that it will require approximately $10 million to fully implement its business plan. The company is exploring various financing options, including equity and convertible debt, to secure the necessary funds. However, management has acknowledged the uncertainty surrounding its ability to raise capital and the potential impact on its operations and financial stability. The company remains committed to its mission of leveraging AI technologies to transform businesses and improve operational efficiencies.